AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Immunotherapy company provides update on late-stage adjuvant programs.
2004 JAN 7 - (NewsRx.com & NewsRx.net) -- Corixa Corp. (CRXA) provided an update on two late stage potential products containing Corixa's MPL adjuvant featured during GlaxoSmithKline's (GSK) recent Research & Development Meeting with investors.
Under current license agreements, GSK incorporates Corixa's MPL adjuvant in several of its vaccines in development, including Cervarix vaccine for the prevention of human papillomavirus (HPV) infection and Simplirix vaccine for the prevention of genital herpes. In a presentation to its investors in London on December 3, 2003, GSK highlighted a variety of programs, including Cervarix and Simplirix containing Corixa's MPL adjuvant, as promising and novel treatments with considerable commercial potential.
Genital herpes is an infection caused by the herpes simplex virus (HSV). There are two types of HSV - HSV-1 and HSV-2 - and both can cause genital herpes. According to the U.S. Centers for Disease Control and Prevention, 45 million people in the United States ages 12 and older, or 1 out of 5 of the total adolescent and adult population, are infected with HSV-2. Nationwide, since the late 1970s, the number of people with genital herpes infection has increased 30%.
Thirteen clinical trials with more than 12,000 volunteers have been completed evaluating Simplirix vaccine containing Corixa's MPL adjuvant. Results from two double-blind, randomized ...
- HSV-1 is likely cause of new genital infections: current prevalence estimates...
- Magazine article from: Skin & Allergy News Mechcatie, Elizabeth August 1, 2005 700+ words
...current estimates of genital herpes from national seroprevalence studies include only HSV-2 infections, they...documenting the emergence of HSV-1 as a cause of primary genital herpes infections date to 1990, when HSV-1 was found to have...
- Glaxo Wellcome and Cantab Commence Phase II Trials with DISC HSV Genital Herpes...
- Press release article from: PR Newswire November 4, 1999 700+ words
...trial with its DISC HSV vaccine for genital herpes. The vaccine is...demonstrate DISC HSV's potential both to treat and prevent genital herpes. The vaccine has...treatment of recurrent genital herpes. The DISC HSV Product DISC (Disabled...
- Cantab Reports Positive Phase I Clinical Trial Results for DISC HSV Genital...
- Press release article from: PR Newswire September 23, 1999 700+ words
...clinical trial with its DISC HSV vaccine for genital herpes being developed in collaboration...endorse the potential of DISC HSV in treating and preventing genital herpes." Detailed findings included: * DISC HSV was demonstrated to have an...
- HSV-2/Genital Herpes Linked to HIV in South Africa.(Brief Article)(Statistical...
- Newspaper article from: AIDS Weekly March 6, 2000 700+ words
...analyses. The authors found that HSV-2 is a more common etiology...Africa; serologic evidence of HSV-2 infection and current cases of genital herpes are strongly associated with...reported in this study are: * HSV-2 is a more common etiology...
- Oligonucleotide-based topical immunotherapy against HSV-2 has promise.(genital...
- Magazine article from: Women's Health Weekly January 9, 2003 700+ words
...application as treatment for genital herpes. "Synthetic oligonucleotides...simplex virus type 2 (HSV-2) infection. For...p<0.01). "HSV-2 is shed from the...had no direct effect on HSV-2 replication in vitro...treatment and control of genital herpes in humans." Pyles and...
- Suppressive TX cuts transmission of genital herpes: susceptible partners in the...
- Magazine article from: OB GYN News Boschert, Sherry December 1, 2002 700+ words
...couples in which one partner has genital herpes and the other doesn't...couples in which one partner had genital herpes simplex virus 2 (HSV-2) and the other partner...susceptible" partners to test for HSV-2 antibodies; checked the...
- Xenova Group plc Results of TA-HSV Phase II Trial For the Treatment of Genital...
- Press release article from: PR Newswire October 10, 2001 700+ words
...GlaxoSmithKline (GSK), with TA-HSV (a therapeutic vaccine...for the treatment of genital herpes). Analysis has shown...conducted amongst 483 HSV-2 seropositive patients...symptomatic recurrent genital herpes. No significant difference...
- Immunization With Mutated HSV-2 May Prevent Transmission.(herpes simplex virus...
- Newspaper article from: Vaccine Weekly March 14, 2001 700+ words
...of herpes simplex virus 2 (HSV-2) may prevent transmission of genital herpes. The vaccine seems to work...Morrison and colleagues report. HSV-2 is a sexually transmitted...with a replication-defective HSV-2 vaccine prototype strain...
